Macrophages are key orchestrators of the innate immune response with a dynamic role in the promotion and resolution of inflammation. Macrophage polarization to a pro-inflammatory or anti-inflammatory phenotype must be tightly controlled to maintain appropriate responses to stimuli as well as to maintain tissue homeostasis. The nutrient and energy sensor Mammalian Target of Rapamycin (mTOR) integrates upstream signals from the PI3K/Akt pathway to orchestrate cellular protein, lipid, and glucose metabolism. This key metabolic pathway has been implicated in T-helper cell skewing and in the innate immune regulation. The mechanisms of innate immune regulation by mTOR are currently unclear as most studies use pharmacological inhibitors with potential off target effects. In this study, we use a novel model of TSC1 deficiency in myeloid lineage cells to elucidate a role for mTOR in macrophage polarization. We show, for the first time, that Tsc1-deficiency and constitutive mTORC1 activity in macrophages leads to a marked defect in M2 polarization when stimulated with the Th2 cytokine IL-4. Tsc1-deficient macrophages display attenuated Akt signaling in response to IL-4 consistent with negative feedback of mTORC1 on upstream IRS2/PI3K signaling, and we demonstrate that this parallel signaling pathway is critical for induction of a subset of M2 markers. Tsc1-deficient macrophages fail to upregulate the M2 genes Pgc-1!, Arg-1, Fizz-1, and Mgl1 in addition to other M2 markers despite normal STAT6 signaling in response to IL-4. Consistent with downregulation of Pgc-1!, Tsc1-deficient macrophages also display defects in fatty acid metabolism and mitchochondrial biogenesis. Furthermore, LPS stimulation in Tsc-1 deficient macrophages leads to an enhanced inflammatory response with increased production of pro-inflammatory cytokines. We believe that Tsc1-deficient macrophages are a model of constitutive mTORC1 activity akin to obesity, where chronic nutrient excess leads to increases in mTORC1 activity, attenuation of IRS/PI3K/Akt signaling, and defective M2 polarization of macrophages in metabolic tissues.

Dissertação de mestrado integrado conduzida na Universidade de Maryland / Tese de mestrado integrado. Engenharia Química. Universidade do Porto. Faculdade de Engenharia. 2011

The present work addresses outstanding questions within the field of primary mitochondrial disease biology and treatment, by incorporating methods from structural biology, molecular biology, and animal studies. First, we utilize a mouse model of mitochondrial deoxyribose nucleic acid (mtDNA) disease to demonstrate the potential therapeutic benefit of low-dose chronic rapamycin treatment. Interestingly, rapamycin therapy significantly extends survival, but does so in the absence of correcting the underlying mitochondrial defect. Next, we focus on human cellular models of mtDNA-based diseases, and show that rapamycin treatment does not induce mitochondrial quality control-mediated clearance of pathogenic mtDNA mutation-harboring organelles. Finally, we investigate a mitochondrial disease phenotype at the level of the organelle, by utilizing in situ cryo-electron tomography to demonstrate the ultrastructural consequences of a pathogenic mutation affecting mitochondrial energy production. We conclude by highlighting the insights into disease biology and treatment that can be gained through a multi-level approach integrating techniques from multiple biomedical fields.

The PI3K/Akt/mTOR and MAPK pathways are frequently altered in ovarian cancer cells, making them potential candidates for targeted therapy. A more complete understanding of the complex interactions between the different proteins within the two pathways would assist in developing more effective treatment strategies to help overcome therapy resistance. The purpose of this project was to understand the phosphoproteomic changes in response to PI3K/mTOR inhibition in ovarian cancer cells and to identify potential mechanisms that may lead to targeted therapy resistance. To investigate the effect of inhibiting PI3K/mTOR at the cellular level in ovarian cancer, PI3K (LY294002), mTOR (rapamycin) and dual PI3K/mTOR (BEZ235) inhibitors were used to treat a panel of ovarian cancer cell lines. All tested cells, irrespective of PI3K/Akt/mTOR and MAPK pathways mutational status, responded to the three inhibitors. BEZ235 treatment produced greater cell inhibition than the monotargeted agents, while PTENmutated cell lines were more responsive to mTOR blockade than inhibition of PI3K alone. The phosphoproteomic changes in the cell lines were evaluated over a time course after treatment with the inhibitors, stimulated by heregulin, and studied using reverse phase protein array analysis. The results revealed that the decreased expression of pAkt (Thr308) appears to be a biomarker of sensitivity for LY294002 and BEZ235 in both PEO4 and A2780 cells, while upregulation of pAkt (Ser473) is an indicator for effective rapamycin treatment within the same cell lines. Increased pAkt (Ser473) expression after rapamycin treatment in PEO4 cells is believed to be due to the S6K1-mTORC2-Akt feedback loop. It was observed that pERK was upregulated upon BEZ235 treatment, which suggested the presence of cross talk between the PI3K/Akt/mTOR and MAPK pathways. A combination of BEZ235 and PD-0325901 (MEK inhibitor) treatments inhibited both pAkt (Ser473) and pERK, which also produced significant inhibition in cell proliferation compared to monotherapy treatment. The data also revealed a novel finding in ovarian cancer that prolonged (24h) treatment with rapamycin sensitises mTORC2 in PEO4 cells under heregulin stimulation. Moreover, network correlation and clustering analysis using the phosphoproteomic data identified significant correlations between the expression of pmTOR (Ser2481), and both p-cRaf (Ser259 and Ser338). Sin1 knockdown was performed in PEO4 cells and showed significant downregulation in the expression of pAkt (Ser473) and upregulation in pERK expression, indicating the role of Sin1 to regulate both the PI3K/Akt/mTOR and MAPK pathways potentially via mTORC2 and Ras. Phosphoproteomic profiling was performed on 469 ovarian cancer tissue samples using TMA and IHC analysis. Several significant associations were discovered between the phosphoproteomic data and the different clinicopathological parameters. High expression of pmTOR (Ser2448) was correlated with poorer overall survival in patients with ovarian endometrioid carcinoma compared to patients with low expression (p < 0.024). This implies that pmTOR (Ser2448) expression may potentially be a prognostic marker for patients with ovarian endometrioid carcinoma. In conclusion, I present dynamic phosphoproteomic profiling of the PI3K/Akt/mTOR and MAPK pathways in ovarian cancer, suggesting novel feedback loops and cross talk that could play a role in resistance mechanisms to these therapies. Combination treatment showed an additive effect on cell growth offering an approach to overcome drug resistance.

名古屋大学博士学位論文 学位の種類:博士（医療技術学）（課程）学位授与年月日:平成21年3月25日

published_or_final_version / Medicine / Doctoral / Doctor of Philosophy

Thesis (Ph. D.)--Rutgers University, 2007. / "Graduate Program in Computational Biology and Molecular Biophysics." Includes bibliographical references (p. 86-94).

Thesis (M. Phil.)--University of Hong Kong, 2007. / Also available in print.

Thesis (M. Phil.)--University of Hong Kong, 2007. / Includes bibliographical references (leaves 102-135) Also available in print.

Understanding the molecular mechanisms that govern productivity and growth of recombinant host cells is essential to devise informed approaches to increase commercial viability and availability of biopharmaceuticals. This work has focused on the roles of the mammalian target of rapamycin complex 1 (mTORC1) signalling pathway in CHO cells, the most widely used expression system in the biopharmaceutical industry. mTORC1 is a master regulator of cell growth, protein synthesis and metabolism in response to availability of nutrients, oxygen and growth factors. Therefore, it was hypothesised that increased activity of mTORC1 enhances growth and productivity of recombinant CHO cells. The study of a recombinant GS-CHO cell line in the serum-free suspension batch culture indicated a gradual decrease in the activity of mTORC1, as defined by the decreased extent of site-specific phosphorylation of two widely ascribed downstream target proteins (ribosomal protein S6 kinase 1 (S6K1) and 4E-BP1, an inhibitor of translation initiation). The decline in the activity of mTORC1 paralleled decreased growth rate, recombinant protein specific productivity and global protein translation. To further clarify the role of the mTOR pathway in cell growth and protein production, cells in batch culture were treated with rapamycin, a specific inhibitor of mTORC1. Treatment with rapamycin stalled the growth of the CHO cell line transiently, but recombinant protein specific productivity, longevity of batch culture, and final antibody titre were greater than control. Rapamycin addition produced discriminating effects on downstream signalling targets, implicating distinct roles for these targets in control of growth and protein synthesis. Engineering the mTORC1 pathway by overexpression of specific components of this pathway (S6K1 and Rheb) generated increased growth and extended viability. Greater proliferation was not associated with improved productivity suggesting highly proliferative phenotypes that prioritise cell growth over synthesis and secretion of recombinant antibody in the recombinant GS-CHO cells examined. Therefore, the engineering of mTORC1 pathway may be beneficial to increase robustness or adaptation to stressed conditions (such as serum- free suspension growth, low nutrition availability and hypoxia).